Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma

Journal of the National Cancer Institute

Volumn 92, Issue 16, 2000, Pages 1316-1321

  Bani Hani, Kamal ^a   Martin, Iain G ^a   Hardie, Laura J ^b   Mapstone, Nicholas ^c   Briggs, Jackie A ^b   Forman, David ^d   Wild, Christopher P ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Algernon Firth Building ^*  (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0034674912     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.16.1316     Document Type: Article

References (26)

1. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
2. The rising trend in oesophageal adenocarcinoma and gastric cardia
3. Etiology of Barrett's metaplasia and esophageal adenocarcinoma
4. Barrett's esophagus and esophageal adenocarcinoma
5. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux
6. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia
7. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
8. Survival of cancer patients in Europe - The EUROCARE-2 study
9. A guide for surveillance of patients with Barrett's esophagus
10. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review
11. Barrett's esophagus: Ordering the events that lead to cancer
12. Molecular precursor lesions in oesophageal cancer
13. Increased expression of the cyclin D1 gene in Barrett's esophagus
14. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus
15. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus
16. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus
17. Barrett's-esophagus, dysplasia, and adenocarcinoma
18. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7
19. The columnar-lined esophagus. History, terminology, and clinical issues
20. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age
21. Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1
22. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia
23. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia
24. Role of p53 assessment in management of Barrett's esophagus
25. Barrett's esophagus